Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, Refetoff S, Nikiforov YE, Fagin JA.

Cancer Res. 2005 May 15;65(10):4238-45.

2.

Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model.

Orim F, Bychkov A, Shimamura M, Nakashima M, Ito M, Matsuse M, Kurashige T, Suzuki K, Saenko V, Nagayama Y, Yamashita S, Mitsutake N.

Thyroid. 2014 Mar;24(3):502-10. doi: 10.1089/thy.2013.0038. Epub 2014 Jan 15.

3.

BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.

Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A, Elisei R.

Endocr Relat Cancer. 2008 Jun;15(2):511-20. doi: 10.1677/ERC-07-0130.

4.

BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.

Costa AM, Herrero A, Fresno MF, Heymann J, Alvarez JA, Cameselle-Teijeiro J, García-Rostán G.

Clin Endocrinol (Oxf). 2008 Apr;68(4):618-34. Epub 2007 Dec 5.

PMID:
18070147
5.

Postnatal expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma.

Shimamura M, Nakahara M, Orim F, Kurashige T, Mitsutake N, Nakashima M, Kondo S, Yamada M, Taguchi R, Kimura S, Nagayama Y.

Endocrinology. 2013 Nov;154(11):4423-30. doi: 10.1210/en.2013-1174. Epub 2013 Aug 22.

PMID:
23970782
6.

BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.

Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D.

J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3. Epub 2007 May 8.

PMID:
17488796
7.

BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.

Sykorova V, Dvorakova S, Ryska A, Vcelak J, Vaclavikova E, Laco J, Kodetova D, Kodet R, Cibula A, Duskova J, Hlobilkova A, Astl J, Vesely D, Betka J, Hoch J, Smutny S, Cap J, Vlcek P, Novak Z, Bendlova B.

J Endocrinol Invest. 2010 May;33(5):318-24. doi: 10.3275/6722. Epub 2009 Dec 4.

PMID:
20009493
8.

Childhood thyroid carcinoma with BRAFT1799A mutation shows unique pathological features of poor differentiation.

Kumagai A, Namba H, Mitsutake N, Saenko VA, Ohtsuru A, Ito M, Noh JY, Sugino K, Ito K, Yamashita S.

Oncol Rep. 2006 Jul;16(1):123-6.

PMID:
16786134
9.

Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma.

Baitei EY, Zou M, Al-Mohanna F, Collison K, Alzahrani AS, Farid NR, Meyer B, Shi Y.

J Pathol. 2009 Apr;217(5):707-15. doi: 10.1002/path.2496.

PMID:
19156774
10.

Expression of iodine metabolism genes in human thyroid tissues: evidence for age and BRAFV600E mutation dependency.

Espadinha C, Santos JR, Sobrinho LG, Bugalho MJ.

Clin Endocrinol (Oxf). 2009 Apr;70(4):629-35. doi: 10.1111/j.1365-2265.2008.03376.x. Epub 2008 Aug 15.

PMID:
18710471
11.

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC, Cheng JT.

Clin Endocrinol (Oxf). 2005 Oct;63(4):461-6.

PMID:
16181240
12.

Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells.

Mitsutake N, Knauf JA, Mitsutake S, Mesa C Jr, Zhang L, Fagin JA.

Cancer Res. 2005 Mar 15;65(6):2465-73.

13.

BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas.

Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, Marino C, Avenia N, Rossi ED, Fadda G, Cavaliere A, Ribacchi R, Falorni A, Pontecorvi A, Pacini F, Pinchera A, Santeusanio F.

J Clin Endocrinol Metab. 2004 May;89(5):2414-20.

PMID:
15126572
14.

Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.

Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, Faviana P, Mannavola D, Moretti S, Rossi S, Sculli M, Bottici V, Beck-Peccoz P, Pacini F, Pinchera A, Santeusanio F, Elisei R.

Endocr Relat Cancer. 2006 Jun;13(2):455-64.

15.

Reduced expression of THRβ in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression.

Rosignolo F, Maggisano V, Sponziello M, Celano M, Di Gioia CR, D'Agostino M, Giacomelli L, Verrienti A, Dima M, Pecce V, Durante C.

J Endocrinol Invest. 2015 Dec;38(12):1283-9. doi: 10.1007/s40618-015-0309-4. Epub 2015 May 24.

PMID:
26003825
16.

The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.

Riesco-Eizaguirre G, Rodríguez I, De la Vieja A, Costamagna E, Carrasco N, Nistal M, Santisteban P.

Cancer Res. 2009 Nov 1;69(21):8317-25. doi: 10.1158/0008-5472.CAN-09-1248. Epub 2009 Oct 27.

17.

BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.

Gu LQ, Li FY, Zhao L, Liu Y, Zang XX, Wang TX, Chen HP, Ning G, Zhao YJ.

Thyroid. 2009 Apr;19(4):347-54. doi: 10.1089/thy.2008.0246.

PMID:
19355825
18.

Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.

Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA.

J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6. doi: 10.1210/jc.2013-2383. Epub 2013 Jul 5.

19.

High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA.

Cancer Res. 2003 Aug 1;63(15):4561-7.

20.

BRAFV600E-Associated Gene Expression Profile: Early Changes in the Transcriptome, Based on a Transgenic Mouse Model of Papillary Thyroid Carcinoma.

Rusinek D, Swierniak M, Chmielik E, Kowal M, Kowalska M, Cyplinska R, Czarniecka A, Piglowski W, Korfanty J, Chekan M, Krajewska J, Szpak-Ulczok S, Jarzab M, Widlak W, Jarzab B.

PLoS One. 2015 Dec 1;10(12):e0143688. doi: 10.1371/journal.pone.0143688. eCollection 2015.

Supplemental Content

Support Center